J&J test tracks success of prostate cancer chemotherapy

02/10/2009 | Reuters

A test called CellSearch outperformed other standard tests in monitoring chemotherapy response in patients with metastasized prostate cancer, researchers found. Developed by Johnson & Johnson unit Veridex, CellSearch works by counting the number of circulating tumor cells instead of tracking levels of prostate-specific antigen, as done in conventional tests. The findings suggest that CTC counts may aid prognosis and help doctors understand whether the treatment is working, one of the study authors said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY